Labiotech.eu

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel. The millions of bacteria living within our […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2015

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Adaptimmune has had exciting results regarding the ongoing battle with Synovial Sarcoma. GSK looks to further invest in the expansion of the clinical trial to include two further cohorts. Adaptimmune, with a research base in Oxford (UK) and clinical base in Philadelphia (US), has overcome a milestone in their first cohort for clinical stage I/II T-cell therapy. They […]

September 3, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Sep 2015

Malin has a new Captain aboard to guide and boost its Investments in British Biotechs

Irish life science investment company Malin reshuffles its executive board and gives its former director, Kelly Martin, the new CEO position. The Ex-Elan chief will further push investments in British biotechs. Kelly Martin takes over as CEO of Malin and will balance opportunities and risk in the company’s investments, as well as running day to day […]

September 3, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Sep 2015

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Merck – the German healthcare company has announced the 3 start-ups it plans to adopt into its in-house accelerator program. Two of the participants focus on e-health, while the third, Sulfotools, has developed a cleaner and cheaper method of solid-phase protein synthesis (SPPS). Merck has awarded these start-ups with a €25K investment as a ‘silent’ investor as […]

September 3, 2015 - 4 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Thanks to Alexion Pharmaceuticals, two ultra-rare diseases finally got the first treatment in the European Union, namely Lysosomal acid lipase deficiency (LAL-D) and Pediatric-onset hypophosphatasia. Alexion ramps up its product-pipeline. Until now, the Connecticut-based company, which comprises a market cap of about $38.5Bn (€34,2Bn), has lived mostly on sales of Soliris, the most expensive drug on […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Paris based Sanofi has pulled out of a €176M deal with Californian clinical stage biotech Ardelyx. A licensing deal for a program of pre-clinical candidates treating renal diseases and IBS-C, similar to Tenapanor, was revoked. In February 2015, Fresno County’s Ardelyx announced its pharma-baby, Tenapanor, had passed its stage IIB clinical trials in successfully reducing serum levels of phosphate. […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

So preliminary trial results look good – it could be that the next phase will go forward too. The artificial heart of French pioneer Carmat shows several device failures but overcomes major side effects of former gadgets, such as thromboembolism or haemorrhage. Heart failure is the world’s leading cause of death. In Europe alone, 15 million patients […]

September 2, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 2 Sep 2015

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant. Novo Nordisk, a global endocrine research giant hailing from Copenhagen, Denmark, has plans to acquire two smaller, privately held research companies into its conglomeration. Focusing […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 1 Sep 2015

Does your business plan need some enhancement? The Science4Life Venture Cup 2016 kicks off today!

The application for Germany’s Science4Life Venture Cup 2016 is now open! Join the competition to meet sector-specific experts, benefit from the experiences of former participants and win up to €25k to help your startup to get to the next level. Labiotech knows from its own experience that an aspiring startup needs a convincing business plan […]

September 1, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 1 Sep 2015

Genentech’s Sean Bohen defects to AstraZeneca as CMO

AstraZeneca‘s Senior management team gets reinforced by Sean Bohen, a top executive from Roche‘s subsidiary Genentech. Starting in two weeks, he will push late-stage treatments to the market. It’s been two months since two senior manager left the struggling AstraZeneca. Among them, Briggs Morrison, who left to become new CEO of Syndax. To replace him, […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

Inside Labiotech 1 Sep 2015

1st day of September, Here Comes Labiotech V3

Hi there, Holidays are over, so let’s start September right away in the right dynamic. We worked hard this summer, especially Alexis, our web dev intern, and Nicolas to deliver you this V3 of Labiotech.eu. These are the 5 biggest optimizations (screenshots below): Our map/database is now integrated at www.labiotech.eu/map Company pages from the map […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 1 Sep 2015

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

A new research competition is born. The European Society of Cardiology and Boehringer Ingelheim will award €400k to four research projects treating cardiovascular diseases. Big Pharmas like to give a push to aspiring research projects within their field. GSK is a key partner of the world’s largest life science startup accelerator, namely OneStart. Sanofi is engaged […]

September 1, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gut bacteria growth time can cause disease?

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Malin has a new Captain aboard to guide and boost its Investments in British Biotechs

Startups receive €25K investment as part of Merck’s brand new Accelerator Program

Alexion launches a duo of new therapies for ultra-rare diseases in the EU

Arderlyx’s ‘hot potato’: Sanofi changes its mind about €175M pre-clinical research deal

Carmat’s Artificial Heart is now inside three patients – how’s it doing?

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Does your business plan need some enhancement? The Science4Life Venture Cup 2016 kicks off today!

Genentech’s Sean Bohen defects to AstraZeneca as CMO

1st day of September, Here Comes Labiotech V3

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!